SCHEMBL1096145

SCHEMBL1096145

COC(=O)c1ccc(N2CCC(O)CC2)c(C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 4/20 0.59
MAPT P10636 4/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 2/20 0.59
HPGD P15428 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HTR7 P34969 3/20 0.46
LMNA P02545 3/20 0.46
POLB P06746 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
SRD5A1 P18405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL382272 0.86 ALDH1A1 (0.59) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL3436339 0.85 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL381764 0.85 HPGD (0.57) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL383205 0.85 MAPT (0.57) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL2773762 0.84 NPC1 (0.72) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL1664707 0.84 HSD17B10 (0.56) ALDH1A1KDM4ESMN1; SMN2ALOX15HSD17B10
SCHEMBL30863572 0.83 WDR5 (0.56) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL26472479 0.83 WDR5 (0.56) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL6508563 0.82 KDM4E (0.54) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL2773168 0.82 KMT2A (0.57) ALDH1A1KDM4EMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153624-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-04-10 US disclosed
EP-2178851-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2011-12-28 EP disclosed
US-20100152166-A1 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2010-06-17 US disclosed
EP-2178851-A1 COMPOUNDS AND METHODS FOR MODULATING FXR Eli Lilly & Company (US) 2010-04-28 EP disclosed
WO-2009012125-A1 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152166-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, FXR1, SLC10A1 ALDH1A1 2124/4885KDM4E 4157/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.